News >

Surgical Challenges Remain Among Recent Successes in Kidney Cancer

Angelica Welch
Published: Monday, Apr 09, 2018

Hyung L. Kim, MD
Hyung L. Kim, MD
Nephrectomy remains an optimal option for the treatment of patients with localized kidney cancer, says Hyung L. Kim, MD, adding that although contested by many in the community, cytoreductive surgery is still considered bene cial for patients with metastatic disease.

In an interview during the meeting, Kim touched on the impact of surgery in the localized and metastatic settings on patients with kidney cancer, as well as the importance of biomarkers.

OncLive®: Can you provide an overview of your presentation on perioperative and systemic therapy in kidney cancer?

Kim: I spoke about adjuvant therapy for kidney cancer. When someone presents with localized disease, we offer them surgery. The operation is called a nephrectomy, which is removing the kidney along with the tumor, but sometimes we can do a partial nephrectomy. The goal of surgery is cure. However, in patients with high-risk disease, the cancer can recur, and it can recur in the lungs or the lymph nodes. The goal of perioperative therapy, or adjuvant therapy, is to try and reduce the risk of metastatic recurrence.

Can you speak to the use of cytoreductive nephrectomy in this space?

A nephrectomy can be done in different settings. It can be done for clinically localized disease, where the goal of treatment is cure, or it can be done in patients who have metastatic disease, where the goal is not cure but to extend survival by reducing disease burden. The latter is called cytoreductive nephrectomy.

In the era of these modern treatments, it is not quite clear if cytoreductive nephrectomy is beneficial. If you ask most urologic surgeons, they still operate the under the assumption that it is beneficial. There are some trials that are directly addressing this question, but those results are not available yet.

Can you discuss the CARMINA and SURTIME trials?

The CARMINA trial has closed enrollment, but we do not know the results yet. This study is looking at the role of cytoreduction in patients with kidney cancer who are receiving sunitinib. It will be very interesting to see what that shows.


... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x